RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Santen Pharmaceutical Co Stock

Santen Pharmaceutical Co Equity 2024

Santen Pharmaceutical Co Equity

306.05 B JPY

Ticker

4536.T

ISIN

JP3336000009

WKN

864318

In 2024, Santen Pharmaceutical Co's equity was 306.05 B JPY, a -9.31% increase from the 337.49 B JPY equity in the previous year.

Santen Pharmaceutical Co Aktienanalyse

What does Santen Pharmaceutical Co do?

Santen Pharmaceutical Co., Ltd. is a Japanese company specializing in the development and marketing of pharmaceutical products and medical devices. With its headquarters in Osaka, Japan, Santen was founded in October 1890 as Fukuhara Helper's Institute Co., Ltd. Santen started as a small contact lens manufacturer and distributor in 1936, focusing on producing and selling high-quality contact lenses. Over time, the company expanded its product offerings to include ophthalmic products such as eye drops and other medications. In the 1990s, Santen further expanded its business by acquiring other companies and establishing its own research and development department to develop innovative products. Today, Santen is part of a global network of companies specializing in the development and marketing of ophthalmic products. Santen operates in various business areas, including ophthalmology, dermatological and anti-rheumatic medications, as well as medical devices and diagnostic instruments. The company has a presence in over 60 countries worldwide, with branches in the USA, Europe, and Asia. In the field of ophthalmology, Santen offers a wide range of products for the treatment of eye diseases such as glaucoma, dry eye, and allergic conditions. The company has also developed advanced devices for ophthalmology, such as lasers for the treatment of various eye diseases. Santen has also invested in dermatological medicine by offering medications for various skin conditions, including acne, psoriasis, and eczema. Additionally, the company provides medical devices for the diagnosis and monitoring of skin conditions. Specializing in the development of anti-rheumatic medications, Santen offers therapies for conditions such as rheumatoid arthritis and psoriatic arthritis. The company has collaborated with other companies to develop innovations in this field. Santen's business model revolves around developing and marketing innovative products for the healthcare industry. The company aims to provide patients worldwide with access to the best treatments and medical devices. Santen prioritizes research and development, investing a significant portion of its revenue in the development of new products. Overall, Santen offers a wide range of products and services that are in high demand in the healthcare sector. The company has established itself as an innovative provider of top-quality solutions in ophthalmology, dermatology, and rheumatology worldwide. With its strong presence in various countries, Santen continues to invest in the research and introduction of new products that can improve the health and well-being of people. Santen Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Santen Pharmaceutical Co's Equity

Santen Pharmaceutical Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Santen Pharmaceutical Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Santen Pharmaceutical Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Santen Pharmaceutical Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Santen Pharmaceutical Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Santen Pharmaceutical Co stock

What is the equity of Santen Pharmaceutical Co this year?

Santen Pharmaceutical Co has equity of 306.05 B JPY this year.

What was the equity of Santen Pharmaceutical Co compared to the previous year?

The equity of Santen Pharmaceutical Co has increased/decreased by -9.31% decreased compared to the previous year.

What impact does a high equity have on investors of Santen Pharmaceutical Co?

A high equity is advantageous for investors of Santen Pharmaceutical Co as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Santen Pharmaceutical Co?

A low equity can be a risk for investors of Santen Pharmaceutical Co, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Santen Pharmaceutical Co affect the company?

An increase in equity of Santen Pharmaceutical Co can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Santen Pharmaceutical Co affect the company?

A reduction in equity of Santen Pharmaceutical Co can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Santen Pharmaceutical Co?

Some factors that can affect the equity of Santen Pharmaceutical Co include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Santen Pharmaceutical Co so important for investors?

The equity of Santen Pharmaceutical Co is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Santen Pharmaceutical Co take to change the equity?

To change equity, Santen Pharmaceutical Co can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Santen Pharmaceutical Co pay?

Over the past 12 months, Santen Pharmaceutical Co paid a dividend of 34 JPY . This corresponds to a dividend yield of about 1.91 %. For the coming 12 months, Santen Pharmaceutical Co is expected to pay a dividend of 34.87 JPY.

What is the dividend yield of Santen Pharmaceutical Co?

The current dividend yield of Santen Pharmaceutical Co is 1.91 %.

When does Santen Pharmaceutical Co pay dividends?

Santen Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Santen Pharmaceutical Co?

Santen Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Santen Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 34.87 JPY are expected. This corresponds to a dividend yield of 1.96 %.

In which sector is Santen Pharmaceutical Co located?

Santen Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Santen Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Santen Pharmaceutical Co from 12/1/2024 amounting to 17 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Santen Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Santen Pharmaceutical Co in the year 2023?

In the year 2023, Santen Pharmaceutical Co distributed 32 JPY as dividends.

In which currency does Santen Pharmaceutical Co pay out the dividend?

The dividends of Santen Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Santen Pharmaceutical Co

Our stock analysis for Santen Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Santen Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.